Vaxxinity Revenue

Revenue

n/a

Revenue Growth

n/a

P/S Ratio

n/a

Revenue / Employee

n/a

Employees

Market Cap

12.68K

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	-	-	-
Dec 31, 2022	-	-	-
Dec 31, 2021	66.00K	-491.00K	-88.15%
Dec 31, 2020	557.00K	-	-
Dec 31, 2019	-	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Marizyme	183.42K
Seelos Therapeutics	2.01M
RVL Pharmaceuticals	36.92M
Infinity Pharmaceuticals	2.57M
American Oriental Bioengineering	121.58M
Gelesis Holdings	12.14M
Nanobac Pharmaceuticals	17.62K

Revenue Rankings

Vaxxinity News

2 years ago - Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine - GlobeNewsWire
2 years ago - Vaxxinity Issues Shareholder Letter - GlobeNewsWire
2 years ago - Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock - GlobeNewsWire
2 years ago - Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting - GlobeNewsWire
2 years ago - Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates - GlobeNewsWire
2 years ago - Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024 - GlobeNewsWire
2 years ago - Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published - GlobeNewsWire
2 years ago - Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024 - GlobeNewsWire

More News